Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.

MLA

Cohen, Stanley B., et al. “Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.” Advances in Therapy, vol. 38, no. 1, Jan. 2021, pp. 226–48. EBSCOhost, https://doi.org/10.1007/s12325-020-01501-z.

APA

Cohen, S. B., Greenberg, J. D., Harnett, J., Madsen, A., Smith, T. W., Gruben, D., Zhang, R., Lukic, T., Woolcott, J., Dandreo, K. J., Litman, H. J., Blachley, T., Lenihan, A., Chen, C., Rivas, J. L., & Dougados, M. (2021). Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Advances in Therapy, 38(1), 226–248. https://doi.org/10.1007/s12325-020-01501-z

Chicago

Cohen, Stanley B, Jeffrey D Greenberg, James Harnett, Ann Madsen, Timothy W Smith, David Gruben, Richard Zhang, et al. 2021. “Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.” Advances in Therapy 38 (1): 226–48. doi:10.1007/s12325-020-01501-z.